Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca appoints non-executive director

AstraZeneca appoints non-executive director

25th July 2007

AstraZeneca has announced the appointment of Bo Angelin to the board of directors of the firm as a non-executive director. This appointment will take effect immediately.

Currently, Mr Angelin is head of the department of endocrinology, metabolism and diabetes at the Karolinska University Hospital in Stockholm and professor of clinical metabolism at Karolinska Institutet.

His research group is currently looking to find new methods of eliminating cholesterol in the body by exploring the regulation of lipid metabolism in the liver by genes, diets and hormones.

The company reports that no disclosure obligations under paragraphs one to six of the UK Listing Authority’s Listing Rules arise as a result of Mr Angelin’s appointment to the board of directors.

Louis Schweitzer, chairman of AstraZeneca, said: “I am delighted that Bo Angelin has agreed to join us.

“His considerable experience in medical research and the practice of medicine will be of great benefit to the work of the board.”

Last month, AstraZeneca announced the planned resignation of Jon Symonds, chief financial officer at the firm, at the end of July.

The company reported that it is currently engaged in a search outside of AstraZeneca for a replacement for Mr Symonds.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.